Skip to main content
Top
Published in: Infection 5/2013

01-10-2013 | Brief Report

High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM

Authors: C. Hoffmann, H. Sahly, A. Jessen, P. Ingiliz, H.-J. Stellbrink, S. Neifer, K. Schewe, S. Dupke, A. Baumgarten, A. Kuschel, I. Krznaric

Published in: Infection | Issue 5/2013

Login to get access

Abstract

Purpose

There is increasing evidence that shigellosis is a predominantly sexually transmitted disease among men who have sex with men (MSM) and that infection with the human immunodeficiency virus (HIV) is a risk factor for shigellosis.

Methods

Retrospective analysis of antibiotic resistance profiles of Shigella species isolated from stool specimens of patients presenting with diarrhea from January 2010 to July 2012 in three German outpatient clinics specialized in HIV care.

Results

Among 79 cases of Shigella sonnei, 56 occurred in HIV-infected MSM, while 23 were observed in HIV-negative MSM. High resistance rates (>90 %) were found for doxycycline, tetracycline, aminoglycosides, all cephalosporins of first and second generations tested, and trimethoprim/sulfamethoxazole. In total, 54 % of cases were resistant to ciprofloxacin. Compared to negative subjects, HIV-infected MSM had a significantly higher rate of quinolone resistance. For ciprofloxacin, the resistance rates were 66 versus 24 %, respectively (p = 0.0016). Individual resistance patterns did not indicate that this was due to a limited outbreak. Rates of resistance to other antibiotics than quinolones showed no differences between HIV-infected and HIV-negative cases. No resistance was found for carbapenems or newer cephalosporins such as ceftriaxone.

Conclusions

The high rates of S. sonnei isolates resistant to quinolones and other traditional antibiotics are of concern. Innovative prevention efforts are urgently needed. The empirical use of quinolones in HIV-infected patients presenting with S. sonnei infection is no longer recommended.
Literature
2.
go back to reference Niyogi SK. Increasing antimicrobial resistance—an emerging problem in the treatment of shigellosis. Clin Microbiol Infect. 2007;13:1141–3.PubMedCrossRef Niyogi SK. Increasing antimicrobial resistance—an emerging problem in the treatment of shigellosis. Clin Microbiol Infect. 2007;13:1141–3.PubMedCrossRef
3.
go back to reference Baer JT, Vugia DJ, Reingold AL, Aragon T, Angulo FJ, Bradford WZ. HIV infection as a risk factor for shigellosis. Emerg Infect Dis. 1999;5:820–3.PubMedCrossRef Baer JT, Vugia DJ, Reingold AL, Aragon T, Angulo FJ, Bradford WZ. HIV infection as a risk factor for shigellosis. Emerg Infect Dis. 1999;5:820–3.PubMedCrossRef
4.
go back to reference Aragón TJ, Vugia DJ, Shallow S, Samuel MC, Reingold A, Angulo FJ, Bradford WZ. Case–control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. Clin Infect Dis. 2007;44:327–34.PubMedCrossRef Aragón TJ, Vugia DJ, Shallow S, Samuel MC, Reingold A, Angulo FJ, Bradford WZ. Case–control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. Clin Infect Dis. 2007;44:327–34.PubMedCrossRef
5.
go back to reference Robert Koch Institut. Epidemiologisches Bulletin. 27 September 2010/Nr. 38. 2010. Robert Koch Institut. Epidemiologisches Bulletin. 27 September 2010/Nr. 38. 2010.
6.
go back to reference Marcus U, Zucs P, Bremer V, Hamouda O, Prager R, Tschaepe H, Futh U, Kramer M. Shigellosis—a re-emerging sexually transmitted infection: outbreak in men having sex with men in Berlin. Int J STD AIDS. 2004;15:533–7.PubMedCrossRef Marcus U, Zucs P, Bremer V, Hamouda O, Prager R, Tschaepe H, Futh U, Kramer M. Shigellosis—a re-emerging sexually transmitted infection: outbreak in men having sex with men in Berlin. Int J STD AIDS. 2004;15:533–7.PubMedCrossRef
7.
go back to reference Sivapalasingam S, Nelson JM, Joyce K, Hoekstra M, Angulo FJ, Mintz ED. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother. 2006;50:49–54.PubMedCrossRef Sivapalasingam S, Nelson JM, Joyce K, Hoekstra M, Angulo FJ, Mintz ED. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother. 2006;50:49–54.PubMedCrossRef
8.
go back to reference Vrints M, Mairiaux E, Van Meervenne E, Collard JM, Bertrand S. Surveillance of antibiotic susceptibility patterns among Shigella sonnei strains isolated in Belgium during the 18-year period 1990 to 2007. J Clin Microbiol. 2009;47:1379–85.PubMedCrossRef Vrints M, Mairiaux E, Van Meervenne E, Collard JM, Bertrand S. Surveillance of antibiotic susceptibility patterns among Shigella sonnei strains isolated in Belgium during the 18-year period 1990 to 2007. J Clin Microbiol. 2009;47:1379–85.PubMedCrossRef
9.
go back to reference Gu B, Cao Y, Pan S, Zhuang L, Yu R, Peng Z, Qian H, Wei Y, Zhao L, Liu G, Tong M. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009. Int J Antimicrob Agents. 2012;40:9–17.PubMedCrossRef Gu B, Cao Y, Pan S, Zhuang L, Yu R, Peng Z, Qian H, Wei Y, Zhao L, Liu G, Tong M. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009. Int J Antimicrob Agents. 2012;40:9–17.PubMedCrossRef
10.
go back to reference Gaudreau C, Ratnayake R, Pilon PA, Gagnon S, Roger M, Lévesque S. Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis. 2011;17:1747–50.PubMedCrossRef Gaudreau C, Ratnayake R, Pilon PA, Gagnon S, Roger M, Lévesque S. Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis. 2011;17:1747–50.PubMedCrossRef
11.
go back to reference Folster JP, Pecic G, Bowen A, Rickert R, Carattoli A, Whichard JM. Decreased susceptibility to ciprofloxacin among Shigella isolates in the United States, 2006 to 2009. Antimicrob Agents Chemother. 2011;55:1758–60.PubMedCrossRef Folster JP, Pecic G, Bowen A, Rickert R, Carattoli A, Whichard JM. Decreased susceptibility to ciprofloxacin among Shigella isolates in the United States, 2006 to 2009. Antimicrob Agents Chemother. 2011;55:1758–60.PubMedCrossRef
12.
go back to reference Ruiz J, Pons MJ, Gomes C. Transferable mechanisms of quinolone resistance. Int J Antimicrob Agents. 2012;40:196–203.PubMedCrossRef Ruiz J, Pons MJ, Gomes C. Transferable mechanisms of quinolone resistance. Int J Antimicrob Agents. 2012;40:196–203.PubMedCrossRef
13.
go back to reference Dalhoff A. Resistance surveillance studies: a multifaceted problem—the fluoroquinolone example. Infection. 2012;40:239–62.PubMedCrossRef Dalhoff A. Resistance surveillance studies: a multifaceted problem—the fluoroquinolone example. Infection. 2012;40:239–62.PubMedCrossRef
14.
go back to reference Enders M, Turnwald-Maschler A, Regnath T. Antimicrobial resistance of Neisseria gonorrhoeae isolates from the Stuttgart and Heidelberg areas of southern Germany. Eur J Clin Microbiol Infect Dis. 2006;25:318–22.PubMedCrossRef Enders M, Turnwald-Maschler A, Regnath T. Antimicrobial resistance of Neisseria gonorrhoeae isolates from the Stuttgart and Heidelberg areas of southern Germany. Eur J Clin Microbiol Infect Dis. 2006;25:318–22.PubMedCrossRef
16.
go back to reference World Health Organization (WHO). International note on antibiotics in the management of shigellosis. Wkly Epidemiol Rec. 2004;79:202–3. World Health Organization (WHO). International note on antibiotics in the management of shigellosis. Wkly Epidemiol Rec. 2004;79:202–3.
Metadata
Title
High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM
Authors
C. Hoffmann
H. Sahly
A. Jessen
P. Ingiliz
H.-J. Stellbrink
S. Neifer
K. Schewe
S. Dupke
A. Baumgarten
A. Kuschel
I. Krznaric
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0501-4

Other articles of this Issue 5/2013

Infection 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.